BCL-201

N/A

Report date: 2023/10/22 20:01:00
NME

Base Information

Drug NameBCL-201
Drug Alias NameBCL-201S-55746Servier-1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsMyelodysplastic SyndromesMultiple MyelomaLymphoma, Mantle-Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporePoland +[10] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLes Laboratoires ServierVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAdir SarlInstitut De Recherches Internationales ServierNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesMultiple MyelomaLymphoma, Mantle-Cell +[7] 

Other Information

ATC CodeN/A
Related LinksN/A